In type 2 diabetes with an A1c greater than 9%, what is the recommended initial pharmacologic therapy?

In type 2 diabetes with an A1c greater than 9%, what is the recommended initial pharmacologic therapy?

• A. Start basal insulin with possible bolus
• B. Start metformin alone
• C. Start a GLP-1 receptor agonist
• D. Start a sulfonylurea

Answer: (A)

When A1c is above 9% in type 2 diabetes, the goal is rapid and reliable glycemic control. Metformin alone typically lowers A1c only modestly, and starting with a noninsulin regimen is unlikely to bring a very high A1c under control quickly enough. Basal insulin provides strong, predictable lowering of fasting glucose and overall A1c and can be started with a simple plan (for example, initiating a basal dose and titrating to fasting targets). If fasting control is achieved but postprandial hyperglycemia persists, prandial (bolus) insulin can be added. The other options are less effective as initial therapy in this scenario. A GLP-1 receptor agonist, while useful, may not achieve the needed A1c reduction quickly when starting from a high baseline. A sulfonylurea can lower glucose but carries hypoglycemia risk and may not provide as robust or durable control as starting basal insulin in a markedly hyperglycemic patient. Therefore, initiating basal insulin with the possibility of adding bolus insulin as needed is the most appropriate initial approach.

When A1c is above 9% in type 2 diabetes, the goal is rapid and reliable glycemic control. Metformin alone typically lowers A1c only modestly, and starting with a noninsulin regimen is unlikely to bring a very high A1c under control quickly enough. Basal insulin provides strong, predictable lowering of fasting glucose and overall A1c and can be started with a simple plan (for example, initiating a basal dose and titrating to fasting targets). If fasting control is achieved but postprandial hyperglycemia persists, prandial (bolus) insulin can be added.

The other options are less effective as initial therapy in this scenario. A GLP-1 receptor agonist, while useful, may not achieve the needed A1c reduction quickly when starting from a high baseline. A sulfonylurea can lower glucose but carries hypoglycemia risk and may not provide as robust or durable control as starting basal insulin in a markedly hyperglycemic patient. Therefore, initiating basal insulin with the possibility of adding bolus insulin as needed is the most appropriate initial approach.